BLRX (BioLineRx Ltd.) Net earnings per share growth this year

BLRX (BioLineRx Corporation) - company brandmark

The development of BioLineRx Ltd. (BLRX) relies on internal innovation cycles and successful trials, rendering the company resilient to market volatility. Revenues are based on the sale of Aphexda in hematology centers via insurance reimbursements. Commercialization efficiency and market share capture determine the financial foundation. The annual EPS growth rate demonstrates profit dynamics, while the 0.00 indicator reflects the issuer's fundamental ability to service its obligations.

Earnings per share growth in current year: BioLineRx Ltd (BLRX) for 07/04/2022 - 11/10/2026

Financial and market metric breakdowns for BioLineRx Ltd. (BLRX)

- stock quotes and analyst forecast:
Share Price BioLineRx Ltd|BLRX - Analyst Consensus Forecast
- business market valuation indicators:
Market Valuation BioLineRx Corporation|BLRX - Total Company Value
- company book value details:
Net Asset Value per Share BioLineRx|BLRX - Company Book Value|Market Value to Book Value Ratio biolinerx.com|BLRX - Aggregate Company Assets
- debt and liquidity details:
Debt to Capital BioLineRx Ltd.|BLRX - Long-Term Debt to Capital|Short-Term Indebtedness to Equity biolinerx.com|BLRX - Company Total Debt|Debts to Book Value BioLineRx Corporation|BLRX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings BioLineRx|Intermediate Liquidity Ratio biolinerx.com
- company profitability and valuation multiples indicators:
BLRX - Net Profit|Expected Net Income BioLineRx Ltd.|BLRX - P/E Multiple|Projected Price to Earnings Ratio BioLineRx Corporation|BLRX - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation BioLineRx Corporation|BLRX - Operating profit EBITDA|Net earnings per share (EPS TTM) BioLineRx|BLRX - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months biolinerx.com|BLRX - Net earnings per share growth this year|Expected net earnings per share growth next year BioLineRx Ltd.
Summary company analysis:BLRX BioLineRx Ltd
Signature product of BioLineRx Ltd.

This indicator measures the year-over-year growth rate of net earnings per common share. Positive momentum confirms the effectiveness of business scaling, while volatility signals potential risks. By analyzing the annual variability of earnings per share, an investor assesses the stability of cash flow. For BioLineRx Ltd. (BLRX), this metric reflects the complexities of drug commercialization. The struggle for government budgets with conservative therapy standards directly limits earnings growth.

Key competitors

Earnings per share growth this year INCY|HCM (HUTCHMED Ltd) - Earnings growth in current year|Net earnings per share growth this year Nuvation Corp (NUVB)|Earnings per share growth in current year Day One (DAWN)|MNPR - Earnings per share growth rate in current year|Earnings per share growth in current year Inhibrx Biosciences, Inc. INBX|I-Mab Biopharma Co., Ltd. - Earnings per share growth in current year|FENC - Earnings per share growth in current year|Earnings per share growth rate in current year Heron Therapeutics|NVCT: Earnings growth in current year|Net earnings per share change in current year Coherus BioSciences CHRS|Net earnings per share growth this year CRBP|Earnings per share growth rate in current year Cardiff Oncology Corp CRDF|Net earnings per share growth this year BYSI (BeyondSpring Pharma)|BCAB (bioatla.com) - Earnings per share increase in current year|Lixte Biotechnology - Net earnings per share growth this year|Net earnings per one share growth for the current year CTXR (Citius Pharmaceuticals Inc.)|Cellectar Biosciences, Inc. - Earnings growth in current year|Earnings per share increase in current year CANF (Can-Fite BioPharma Ltd)|APRE: Earnings growth in current year|Earnings per share growth rate in current year Kazia Therapeutics Limited (KZIA)|Earnings per share growth in current year Silexion Therapeutics Corp.|NCNA: Earnings per share increase in current year|Earnings growth in current year CMRX|Earnings growth in current year Cyclacel Pharmaceuticals, Inc. (CYCC)|Earnings per share growth in current year G1 Therapeutics GTHX|KRON (Kronos Bio Corporation) - Earnings per share trend in current year|KTRA: Net earnings per share growth this year|Earnings per share growth rate in current year oncternal.com|PRTG: Earnings growth in current year